scholarly journals Recurrent Vulvovaginal Candidiasis

2021 ◽  
Vol 5 (3) ◽  
pp. 498-507
Author(s):  
Cyntya Sari Sovianti ◽  
Mutia Devi
Keyword(s):  
Quality Of Life ◽  
Mental Health ◽  
Topical Therapy ◽  
Predisposing Factors ◽  
Vulvovaginal Candidiasis ◽  
Suppressive Therapy ◽  
Recurrent Vulvovaginal Candidiasis ◽  
Candida Sp ◽  
Culture Negative

Vulvovaginal candidiasis is a common fungal infection caused by Candida Sp,especially Candida albicans. Recurrent vulvovaginal candidiasis was defined asthe occurrence of four or more episodes of vulvovaginal candidiasis in 12 monthsperiod. As many as 9% of women from various populations have recurrentvulvovaginal candidiasis. Vulvovaginal candidiasis affects the quality of life,mental health, and sexual activity. There are many predisposing factors thatcaused recurrent vulvovaginal candidiasis, such as genetics, host, habit,idiopathic and non-albican candida microbes. Management of recurrentvulvovaginal candidiasis includes elimination of predisposing factors; mycologicalculture diagnosis and identification of specific Candida species; followed bymicrobiological examination to confirm the sensitivity of the azole group toCandida sp. Further, oral, or topical therapy should be continued until the patientis asymptomatic and culture-negative. Patients should receive induction therapyfollowed by maintenance suppressive therapy for six months.

scholarly journals Recurrent Vulvovaginal Candidiasis

2021 ◽  
Vol 5 (5) ◽  
pp. 474-483
Author(s):  
Cyntya Sari Sovianti ◽  
Mutia Devi
Keyword(s):  
Quality Of Life ◽  
Topical Therapy ◽  
Predisposing Factors ◽  
Vulvovaginal Candidiasis ◽  
Suppressive Therapy ◽  
Recurrent Vulvovaginal Candidiasis ◽  
Candida Sp ◽  
Microbiological Examination ◽  
Culture Negative

Vulvovaginal candidiasis is a common fungal infection caused by Candida Sp, especially Candida albicans. Recurrent vulvovaginal candidiasis was defined as the occurrence of four or more episodes of vulvovaginal candidiasis ​​in 12 months period. As many as 9% of women from various populations have recurrent vulvovaginal candidiasis. Vulvovaginal candidiasis affects the quality of life, mental health, and sexual activity. There are many predisposing factors that caused recurrent vulvovaginal candidiasis, such as genetics, host, habit, idiopathic and non-albican candida microbes. Management of recurrent vulvovaginal candidiasis includes elimination of predisposing factors; mycological culture diagnosis and identification of specific Candida species; followed by microbiological examination to confirm the sensitivity of the azole group to Candida sp. Further, oral, or topical therapy should be continued until the patient is asymptomatic and culture-negative. Patients should receive induction therapy followed by maintenance suppressive therapy for six months.

Influence of recurrent vulvovaginal candidiasis on quality of life issues

2019 ◽  
Vol 300 (3) ◽  
pp. 647-650 ◽  
Author(s):  
Eiko I. Fukazawa ◽  
Steven S. Witkin ◽  
Renata Robial ◽  
João G. Vinagre ◽  
Edmund C. Baracat ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Vulvovaginal Candidiasis ◽  
Recurrent Vulvovaginal Candidiasis ◽  
Life Issues

scholarly journals Use of fluconazole in women of reproductive age with vulvovaginal candidiasis

2018 ◽  
pp. 96-102
Author(s):  
E. A. Mezhevitinova ◽  
P. R. Abakarova ◽  
Sh. M. Pogosyan
Keyword(s):  
Quality Of Life ◽  
Vulvovaginal Candidiasis ◽  
Reproductive Age ◽  
Common Disease ◽  
Women Of Reproductive Age ◽  
Recurrent Vulvovaginal Candidiasis ◽  
Group I ◽  
Relapse Therapy

Topicality: vulvovaginal candidiasis (VVC) is a common disease caused by the infectious damage of the vulva and vagina by yeast-like fungi from Candida genus. According to the literature, a VVC episode occurs in 75% of women, and 5-8% of them get a recurring course of the disease. Frequent recurrences of the disease may result in the psychosexual disorder and reduce the women’s quality of life and recurrent vulvovaginal candidiasis (VVC) therapy is still a very difficult task.Purpose of the study: evaluate the efficacy of fluconazole (150 mg) in acute and recurrent vulvovaginal candidiasis.Materials and methods:A total of 89 women of reproductive age with acute and recurrent HCV were enrolled in the study, which were subdivided into 2 groups: the first group included women with acute vulvovaginal candidiasis (AVVC) (n = 51), and the second group - women with recurrent vulvovaginal candidiasis (RVVC) (n = 38). The Group I (AVVC) received fluconazole 150 mg once. Depending on the prescribed therapy, the second group (RVVC) was subdivided into two subgroups: patients in the IIa subgroup received fluconazole 150 mg intravenously, three times, at intervals of 2 days, and women in the IIb subgroup received fluconazole 150 mg for a period of 6 months in addition to the three-fold intake of fluconazole weekly. The follow-up period was 6 months after the end of therapy, during which the frequency of VVC recurrence and the effectiveness of the therapy was evaluated.Results of the study: our data showed that all patients with acute VVC had a discontinuation of symptoms of the disease and a normalization of laboratory parameters after treatment with fluconazole, and after the anti-relapse therapy course the incidence of VVC recurrences was significantly lower compared to the period before anti-relapse therapy (p = 0.038). It was shown that all the investigated strains of C. albicans (100%) were sensitive to fluconazole, and resistance was detected only in 1 strain of C. glabrata and 1 strain of C. krusei. 

scholarly journals Optimization of treatment of recurrent vulvovaginal candidiasis

2019 ◽  
Vol 2 (14) ◽  
pp. 27-30
Author(s):  
L. V. Tkachenko ◽  
N. I. Sviridova ◽  
L. N. Bogatyryova ◽  
I. A. Gritsenko
Keyword(s):  
Quality Of Life ◽  
Menstrual Cycle ◽  
Comparison Group ◽  
Vulvovaginal Candidiasis ◽  
Menstrual Cycles ◽  
Recurrent Vulvovaginal Candidiasis ◽  
The Mean ◽  
Efficacy Of Treatment ◽  
Consecutive Cycle

The purpose of the study was to evaluate the efficacy of treatment of recurrent drug Orungamin depending on the time of occurrence of relapse.Material and methods. 62 women with recurrent candida vulvovaginit is were examined and treated. The mean age of the patients was 35.6 ± 0.7 years. The main group consisted of 32 patients who in the premenstrual period 5 days before the expected date of menstruation were prescribed Orungamin 1 capsule (100 mg) twice a day (200 mg) for 3 days during three consecutive menstrual cycles. The comparison group included women receiving Orungamin three consecutive cycle 3 day 1 capsule (100 mg) 2 times a day, without regard to days of the menstrual cycle.Results. Therapy with Orungamin 100 mg twice a day during the premenstrual period not only helped to increase the effectiveness of the treatment of relapses, but also the quality of life of patients.

Qualifying Quality of Life in Mental Health

PsycCRITIQUES ◽  
2007 ◽  
Vol 52 (33) ◽  
Author(s):  
Itai Danovitch
Keyword(s):  
Quality Of Life ◽  
Mental Health

Mental Health and Quality of Life in Native American Adults

2006 ◽  
Author(s):  
Bethanee Lemesurier ◽  
Jordan Tabb ◽  
Mary Pritchard ◽  
Theodore McDonald
Keyword(s):  
Quality Of Life ◽  
Mental Health ◽  
Native American

Quality of life and mental health of neuropediatric patients

2013 ◽  
Vol 44 (02) ◽  
Author(s):  
A Novak ◽  
K Klaus ◽  
R Seidl ◽  
H Werneck ◽  
M Schubert ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Mental Health

Understanding quality of life and treatment history of patients with Bertolotti syndrome compared with lumbosacral radiculopathy

2019 ◽  
Vol 31 (2) ◽  
pp. 222-228 ◽  
Author(s):  
Joshua L. Golubovsky ◽  
Arbaz Momin ◽  
Nicolas R. Thompson ◽  
Michael P. Steinmetz
Keyword(s):  
Quality Of Life ◽  
Mental Health ◽  
Propensity Score ◽  
Disc Herniation ◽  
Symptom Onset ◽  
Patient Reported Outcomes ◽  
Lumbosacral Radiculopathy ◽  
Patient Reported ◽  
Age And Sex

OBJECTIVEBertolotti syndrome is a rare spinal condition that causes low-back pain due to a lumbosacral transitional vertebra (LSTV), which is a pseudoarticulation between the fifth lumbar transverse process and the sacral ala. Bertolotti syndrome patients are rarely studied, particularly with regard to their quality of life. This study aimed to examine the quality of life and prior treatments in patients with Bertolotti syndrome at first presentation to the authors’ center in comparison with those with lumbosacral radiculopathy.METHODSThis study was a retrospective cohort analysis of patients with Bertolotti syndrome and lumbosacral radiculopathy due to disc herniation seen at the authors’ institution’s spine center from 2005 through 2018. Diagnoses were confirmed with provider notes and imaging. Variables collected included demographics, diagnostic history, prior treatment, patient-reported quality of life metrics, and whether or not they underwent surgery at the authors’ institution. Propensity score matching by age and sex was used to match lumbosacral radiculopathy patients to Bertolotti syndrome patients. Group comparisons were made using t-tests, Fisher’s exact test, Mann-Whitney U-tests, Cox proportional hazards models, and linear regression models where variables found to be different at the univariate level were included as covariates.RESULTSThe final cohort included 22 patients with Bertolotti syndrome who had patient-reported outcomes data available and 46 propensity score–matched patients who had confirmed radiculopathy due to disc herniation. The authors found that Bertolotti syndrome patients had significantly more prior epidural steroid injections (ESIs) and a longer time from symptom onset to their first visit. Univariate analysis showed that Bertolotti syndrome patients had significantly worse Patient-Reported Outcomes Measurement Information System (PROMIS) mental health T-scores. Adjustment for prior ESIs and time from symptom onset revealed that Bertolotti syndrome patients also had significantly worse PROMIS physical health T-scores. Time to surgery and other quality of life metrics did not differ between groups.CONCLUSIONSPatients with Bertolotti syndrome undergo significantly longer workup and more ESIs and have worse physical and mental health scores than age- and sex-matched patients with lumbosacral radiculopathy. However, both groups of patients had mild depression and clinically meaningful reduction in their quality of life according to all instruments. This study shows that Bertolotti syndrome patients have a condition that affects them potentially more significantly than those with lumbosacral radiculopathy, and increased attention should be paid to these patients to improve their workup, diagnosis, and treatment.

Sign in / Sign up

Export Citation Format

Share Document